Speaker Profile

Vice President, Immix Biopharma, Inc.

Mr. Witt leads operations at Immix Biopharma, Inc – an oncology therapeutics firm focused on inhibiting mechanisms underlying the very nature of tumor resistance. Immix is poised to begin first-in-man studies with its lead candidate in 2017. As a volunteer, he also serves on BIOCOM’s Capital Development Committee. Previously, Mr. Witt helped high-growth startups in healthcare, backed by top venture capitalists and angel investors such as Y Combinator, Yuri Milner, 500 Startups, Rock Health, Charles River Ventures, and General Catalyst, move to their next value-inflection points. Through his efforts, products at these companies have reached tens of thousands of physicians and millions of patients across the US. Ryan has also served as a working group member at ONC/DHHS, as a patient advocate, and as a lobbyist around combination therapies and molecular medicine underpinnings (i.e., the predecessor to personalized medicine / precision oncology).


Pricing’s Looming Effect on I/O & PM
Checkpoints and I/O therapies, chemotherapy regimens and oncogenic driver targeted therapies have one result in common – a percentage of patient tumors always recur. Despite mechanisms underlying tumor resistance being known for decades, biopharma has never focused on this therapeutic class due to regulatory and reimbursement frameworks – until now.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).